Recursion Pharmaceuticals
Yahoo Finance • 2 days ago
Biotech Breakout: What's in focus after Moderna's cancer win?
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story
Yahoo Finance • 21 days ago
Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the cur... Full story
Yahoo Finance • 26 days ago
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursio... Full story
Yahoo Finance • last month
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Issued on behalf of MindWalk Holdings Corp. (NASDAQ: HYFT) AUSTIN, Texas, July 24, 2026 /PRNewswire/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely... Full story
Yahoo Finance • last month
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
In Cathie Wood's Ark Genomic Revolution ETF (NYSEMKT: ARKG), as of July 10, the three top holdings are Tempus AI, 10x Genomics, and Twist Bioscience. But digging past the top 10 holdings, there's a $1.8 billion biotech company with a growi... Full story
Yahoo Finance • last month
Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story
Yahoo Finance • 2 months ago
Cathie Wood buys $22.8 million of surging tech stock
Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story
Yahoo Finance • 2 months ago
2 Beaten-Down Stocks That Still Aren't Worth Buying
Buying shares of excellent companies that have fallen out of favor is a great way to earn superior returns over the long run. However, investors should be careful not to catch a falling knife. Corporations often fail to keep up with broade... Full story
Yahoo Finance • 2 months ago
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform... Full story
Yahoo Finance • 2 months ago
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA) and Recursion Pharmaceuticals (NASDAQ:RXRX... Full story
Yahoo Finance • 2 months ago
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story
Yahoo Finance • 2 months ago
Cathie Wood buys $11.5 million of battered tech stock
Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story
Yahoo Finance • 2 months ago
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market
Key Points Artificial intelligence technology giant Nvidia owns a handful of promising stocks. One of these holdings is helping lead the charge of change for an industry that could use a cost-reducing revamp. Although this name poses abov... Full story
Yahoo Finance • 2 months ago
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
Key Points Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds. 10 stocks we like better than Recursion Pharmaceutica... Full story
Yahoo Finance • 3 months ago
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?
Key Points Recursion Pharmaceuticals is using AI to improve how we develop drugs. The company has partnered with several major corporations in this quest. The biotech has yet to show meaningful results from its approach. 10 stocks we lik... Full story
Yahoo Finance • 4 months ago
The Future of Intoxication Detection May Be in Your Voice
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safe... Full story
Yahoo Finance • 4 months ago
Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right Now
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data... Full story
Yahoo Finance • 4 months ago
Recursion Announces Board Transition
Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current te... Full story
Yahoo Finance • 4 months ago
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This... Full story
Yahoo Finance • 4 months ago
Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is accelerating its drug development programs and unlocking cost-savings opportunities thanks to i... Full story
- MS